{"filing":{"accession_number":"0001599298-26-000081","cik":"0001599298","ticker":"SMMT","company_name":"Summit Therapeutics Inc.","form":"8-K","filing_date":"2026-09-15","report_date":"2026-09-15","primary_document":"smmt-20260915.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000081/smmt-20260915.htm"},"events":[{"id":33507,"run_id":30809,"accession_number":"0001599298-26-000081","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Summit announced updated overall survival results from the Phase III HARMONi clinical trial presented at WCLC 2026, showing a statistically significant OS benefit (HR 0.76, p=0.0151) in the June 2026 data cut with longer follow-up, particularly in western patients. While this is clinical trial data rather than a traditional earnings release or regulatory approval, the positive efficacy results for ivonescimab—a lead investigational asset with a pending BLA and November 2026 PDUFA date—represent material operational/clinical progress that would affect investor assessment of the company's pipeline and regulatory prospects.","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-09-15","form":"8-K","submitted_at":null,"items":[{"id":36968,"accession_number":"0001599298-26-000081","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Summit announced updated overall survival results from the Phase III HARMONi clinical trial presented at WCLC 2026, showing a statistically significant OS benefit (HR 0.76, p=0.0151) in the June 2026 data cut with longer follow-up, particularly in western patients. While this is clinical trial data rather than a traditional earnings release or regulatory approval, the positive efficacy results for ivonescimab—a lead investigational asset with a pending BLA and November 2026 PDUFA date—represent material operational/clinical progress that would affect investor assessment of the company's pipeline and regulatory prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T12:45:42.056499+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36968,"accession_number":"0001599298-26-000081","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Summit announced updated overall survival results from the Phase III HARMONi clinical trial presented at WCLC 2026, showing a statistically significant OS benefit (HR 0.76, p=0.0151) in the June 2026 data cut with longer follow-up, particularly in western patients. While this is clinical trial data rather than a traditional earnings release or regulatory approval, the positive efficacy results for ivonescimab—a lead investigational asset with a pending BLA and November 2026 PDUFA date—represent material operational/clinical progress that would affect investor assessment of the company's pipeline and regulatory prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T12:45:42.056499+00:00","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-09-15"}]}